thiophenes has been researched along with Parkinson Disease in 172 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.58) | 18.7374 |
| 1990's | 5 (2.91) | 18.2507 |
| 2000's | 39 (22.67) | 29.6817 |
| 2010's | 113 (65.70) | 24.3611 |
| 2020's | 14 (8.14) | 2.80 |
| Authors | Studies |
|---|---|
| Abe-Takahashi, Y; Chiba, H; Higuchi, M; Kitta, T; Ouchi, M; Shinohara, N; Togo, M | 1 |
| Choe, HK; Choe, Y; Choi, JW; Choi, M; Jang, S; Kim, D; Kim, J; Kim, K; Moon, C; Park, I; Park, SH; Sun, W | 1 |
| Ann Natividad, J; Chaudhuri, KR; Chung-Faye, G; Lau, YH; Leta, V; Metta, V; Parry, M; Rukavina, K | 1 |
| Asakawa, T; Feng, C; Li, C; Qu, Y; Sun, W; Sun, Z; Wang, Q; Yang, T; Yang, Y | 1 |
| Chitkara, D; Pandey, MM; Saha, P | 1 |
| Ghetti, B; Goedert, M; Holton, JL; Klingstedt, T; Ling, H; Nilsson, KPR | 1 |
| Bruno, V; Farcy, N; Karnik, V; Zamorano, C | 1 |
| Anheim, M; Grillon, A; Lipsker, D; Moegle, C; Velter, C | 1 |
| Kieburtz, K; Moreadith, R; Olanow, CW; Standaert, DG; Viegas, TX | 1 |
| Fukuta, Y; Ito, H; Kondo, H; Takayama, T | 1 |
| Fujioka, S; Kamimura, H; Mishima, T; Shibaguchi, H; Tsuboi, Y; Yasutaka, Y | 1 |
| Ibrahim, H; Pooley, J; Richfield, EW; Woodward, Z | 1 |
| Boura, I; Chaudhuri, KR; Jenner, P; Klingelhoefer, L; Leta, V; Raeder, V; Reichmann, H; Trenkwalder, C | 1 |
| Hindmarsh, J; Hindmarsh, S; Lee, M | 1 |
| Ando, H; Doyu, M; Fujikake, A; Fukuoka, T; Hayashi, M; Ito, C; Izumi, M; Kawagashira, Y; Koide, H; Nakashima, K; Niwa, JI; Ogawa, K; Oiwa, H; Okada, Y; Taguchi, S; Tokui, K; Tsunoda, Y; Yasumoto, A; Yuasa, T | 1 |
| D'Elia, A; Di Lazzaro, G; Imbriani, P; Mercuri, NB; Pisani, A; Schirinzi, T | 1 |
| Ji, F; Jiang, R; Su, Z; Xue, R; Zhou, Y; Zhu, X; Zhuo, C | 1 |
| Asgharnejad, M; Bauer, L; Benitez, A; Boroojerdi, B; Chung, SJ; Heidbrede, T; Kim, HJ; Little, A | 1 |
| Aguirre, C; Calvo, B; Del Pozo-Rodríguez, A; Domingo-Echaburu, S; García, M; Isla, A; Lertxundi, U; Marquínez, AC; Solinís, MÁ | 1 |
| Chen, F; Jin, L; Nie, Z | 1 |
| Anan, C; Bhidayasiri, R; Boonpang, K; Chaiwong, S; Jagota, P; Leaknok, A; Penkeaw, N; Rattanachaisit, W; Saksornchai, K; Sringean, J; Thanawattano, C | 1 |
| Asgharnejad, M; Bauer, L; Liu, CF; Liu, YM; Shao, M; Surmann, E; Tao, EX; Wang, J; Xue, HB; Zhang, ZX | 1 |
| D'Elia, A; Imbriani, P; Pisani, A; Schirinzi, T | 1 |
| Iwaki, H; Kondo, H; Nomoto, M; Sakurai, M | 1 |
| Ayuga, Á; Gómez-Arguelles, JM; Marey, J; Moya, M; Ramírez, F; Salvador, A; Valldeoriola, F | 1 |
| Bi, C; Chu, L; Duan, D; Sun, K; Wang, A; Wu, Z; Xu, L; Yan, X; Yu, X | 1 |
| Ferrazzoli, D; Frazzitta, G; Maestri, R; Ortelli, P; Riboldazzi, G | 1 |
| Bauer, L; Elshoff, JP; Goldammer, N; Oortgiesen, M; Pesch, H; Timmermann, L | 1 |
| Asgharnejad, M; Badea, L; Bauer, L; Grieger, F; Markowitz, M; Müller, T; Nondonfaz, X; Timmermann, L; Tolosa, E | 1 |
| Abbruzzese, G; Antonini, A; Berardelli, A; Chaudhuri, KR; Defazio, G; Ferreira, J; Martinez-Martin, P; Rascol, O; Tinazzi, M; Trenkwalder, C | 1 |
| Nakahara, A; Oka, H; Umehara, T | 1 |
| Hattori, N; Ogawa, T; Oyama, G | 1 |
| Asgharnejad, M; Ceravolo, MG; Chaudhuri, KR; Dunac, A; Gomez Esteban, JC; Joeres, L; Pavese, N; Safavi, A; Schuller, JC; Woitalla, D | 1 |
| He, Y; Wang, HT; Wang, L; Yu, G | 1 |
| Hindmarsh, J; Hindmarsh, S; Lee, M; Telford, R | 1 |
| Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; De Massis, P; Lopane, G; Mohamed, S; Nassetti, S; Perrone, A; Riva, R; Sambati, L; Scaglione, C | 1 |
| Albanese, M; Liguori, C; Mercuri, NB; Olivola, E; Pierantozzi, M; Stefani, A | 1 |
| Chen, CH; Chou, YC; Huang, WY; Ju, UH; Kao, CH; Lin, CL; Lin, CS; Lin, KT; Lin, TY; Liu, FC; Shen, CH; Yang, TY | 1 |
| Boroojerdi, B; Carson, S; Heldman, D; Isaacson, SH; Klos, K; Kreitzman, DL; Markowitz, M; McGraw, M; Phillips, M; Revilla, FJ; Terricabras, D; Truong, D; Waln, O; Woltering, F | 1 |
| Fu, F; Huang, Y; Lu, Y; Lv, H; Sha, C; Wang, T; Yu, F; Zhai, R; Zhang, L | 1 |
| Frampton, JE | 1 |
| Ding, ZT; Fei, L; Zhou, D | 1 |
| Fukuda, K; Hirano, M; Isono, C; Kusunoki, S; Nakamura, Y; Ueno, S | 1 |
| Cen, X; Du, G; Guan, X; Li, Y; Liu, W; Tian, J; Ye, L; Yu, P; Yu, X; Zhang, J | 1 |
| Boroojerdi, B; Giladi, N; Surmann, E | 1 |
| Antonini, A; Brown, RG; Friedman, JH; Ghys, L; Martinez-Martin, P; Onofrj, M; Ray Chaudhuri, K; Surmann, E; Trenkwalder, C | 1 |
| Hasegawa, K; Hattori, N; Ikeda, J; Kondo, T; Mizuno, Y; Murata, M; Nomoto, M; Takeuchi, M; Tomida, T | 2 |
| Jenner, P | 1 |
| Waters, C | 1 |
| Lyons, KE; Pahwa, R | 1 |
| Lyons, KE | 1 |
| Chen, ZM; Lei, P; Li, FQ; Li, SS; Peng, GG; Zhou, CQ | 1 |
| Arth, C; Bauer, L; Brunnert, M; Elshoff, JP; Komenda, M; Schmid, M; Timmermann, L | 1 |
| Assogna, F; Caltagirone, C; Fanciulli, A; Pontieri, FE; Spalletta, G | 1 |
| Bandettini di Poggio, M; Bruno, C; Meschini, MC; Nesti, C; Santorelli, FM; Schenone, A | 1 |
| Antonini, A; Calandrella, D; Koutsikos, K; Merello, M; Pilleri, M | 1 |
| Martinez-Martin, P; Zesiewicz, TA | 1 |
| Bang-Andersen, B; Christoffersen, CT; Jensen, KG; Jensen, M; Jørgensen, M; Kristensen, JL; Püschl, A; Risgaard, R | 1 |
| Alonso-Canovas, A; Garcia-Ruiz, PJ; Herranz Barcenas, A; Mahillo Fernandez, I; Martinez Castrillo, JC; Mata, M; Olmedilla Gonzalez, N; Sanchez Alonso, P; Vela, L | 1 |
| Boroojerdi, B; Chaudhuri, KR; Friedman, JH; Ghys, L; Moran, K; Surmann, E; Swick, TJ; Trenkwalder, C | 1 |
| Boroojerdi, B; Chaudhuri, KR; Ghys, L; Kassubek, J; Moran, K; Surmann, E; Trenkwalder, C; Zesiewicz, T | 1 |
| Bauer, L; Borgohain, R; Chaná, P; Elmer, LW; Nicholas, AP; Surmann, E; Thompson, EL; Whitesides, J | 1 |
| Asgharnejad, M; Benitez, A; Edens, H; Fishman, J; Moran, K | 1 |
| Hadgraft, J; Lane, ME; McAfee, DA | 1 |
| Chapman, KL; Dexter, DT; Di Fruscia, P; Fuchter, MJ; Harrison, IF; Jung, M; Khongkow, M; Koltsida, K; Lam, EW; Laohasinnarong, S; Liu, C; Moniot, S; Reynolds, CR; Schmidtkunz, K; Steegborn, C; Sternberg, MJ; Zacharioudakis, E | 1 |
| Boroojerdi, B; Ghys, L; Giladi, N; Jankovic, J; Surmann, E | 1 |
| Hasegawa, K; Hattori, N; Kondo, T; Mizuno, Y; Murata, M; Nomoto, M; Takahashi, M; Takeuchi, M; Tomida, T | 1 |
| Brzozowski, MJ; Jenner, P; Rose, S | 1 |
| Anticoli, S; De Pandis, MF; Fiore, S; Persichino, L | 1 |
| Berkels, R; Grieger, F; Kassubek, J; Lauterbach, T; Müller, T; Timmermann, L; Woitalla, D | 1 |
| Berkels, R; Grieger, F; Lauterbach, T; Lorenzl, S; Sieb, JP; Themann, P; Warnecke, T | 1 |
| Andreas, JO; Braun, M; Cawello, W; Elshoff, JP; Mathy, FX | 1 |
| Bauer, L; Chung, SJ; Ikeda, J; Jeon, BS; Kim, JM; Kim, JW; Singh, P; Thierfelder, S | 2 |
| Hirano, M; Isono, C; Kusunoki, S; Nakamura, Y; Sakamoto, H; Ueno, S | 1 |
| Asgharnejad, M; Boroojerdi, B; Dohin, E; Elmer, LW; Timmermann, L; Woltering, F | 1 |
| Antonini, A; Bauer, L; Chaudhuri, KR; Dohin, E; Oertel, WH; Rascol, O; Reichmann, H; Schmid, M; Singh, P; Tolosa, E | 1 |
| Barthelmes, J; Laffleur, F; Wagner, J | 1 |
| Chini, G; Conte, C; Coppola, G; Davassi, C; Draicchio, F; Fasano, A; Mari, S; Pierelli, F; Ranavolo, A; Serrao, M | 1 |
| Bezdolny, YN; Boiko, AN; Burd, SG; Gasanov, MG; Katunina, EA; Lebedeva, AV; Shykkerimov, RK; Titova, NV | 1 |
| Liguori, C; Marciani, MG; Mercuri, NB; Pierantozzi, M; Placidi, F; Stanzione, P; Stefani, A | 1 |
| Asgharnejad, M; Bauer, L; Chaudhuri, KR; Dohin, E; Nilius, S; Rascol, O; Surmann, E; Zesiewicz, T | 1 |
| Gliyazova, NS; Ibeanu, GC | 1 |
| Hasegawa, Y; Oiwa, K; Yasui, K | 1 |
| Asgharnejad, M; Bauer, L; Boroojerdi, B; Giladi, N; Grieger, F | 1 |
| Asgharnejad, M; Bauer, L; Chen, S; Du, X; Hu, X; Shang, HF; Surmann, E; Zhang, ZX; Zhao, Z | 1 |
| Asgharnejad, M; Barone, P; Bauer, L; Dohin, E; Hauser, RA; Slawek, J; Surmann, E | 1 |
| Mundt-Petersen, U; Odin, P; Timpka, J | 1 |
| Fujioka, S; Futagami, K; Imakyure, O; Shibaguchi, H; Tsuboi, Y; Washiyama, A; Yasutaka, Y | 1 |
| Asgharnejad, M; Bauer, L; Chung, SJ; Jeon, B; Ramirez, F | 1 |
| Guillot, B; Raison-Peyron, N | 1 |
| Antonini, A; Asgharnejad, M; Bauer, L; Boroojerdi, B; Chaudhuri, KR; Grieger, F; Weintraub, D | 1 |
| Albanese, M; Imbriani, P; Liguori, C; Marciani, MG; Mercuri, NB; Pierantozzi, M; Placidi, F; Stanzione, P; Stefani, A | 1 |
| Asgharnejad, M; Bauer, L; Dohin, E; Giladi, N; Nicholas, AP; Poewe, W; Woltering, F | 1 |
| Chen, Y; Lan, D; Wang, Y; Wu, H; Yang, Y; Zhao, Z | 1 |
| Lan, DM; Wang, Y; Wu, H-; Yang, YC; Zhao, ZX | 1 |
| Heald, AH; Livingston, M; Stedman, M; Wyrko, Z | 1 |
| Bauer, L; Fröhlich, H; Kassubek, J; Lauterbach, T; Oehlwein, C; Ransmayr, G; Schroeder, H; Timmermann, L; Will, E | 1 |
| Contin, M; Mohamed, S; Riva, R | 1 |
| Herrman, L; Kinkel, M; Muhlack, S; Müller, T | 1 |
| Nogid, A; Pham, DQ | 1 |
| Andreas, JO; Braun, M; Cawello, W; Hnatkova, K; Hoeckendorff, J; Horstmann, R; Malik, M; Middle, M | 1 |
| Perez-Lloret, S; Rascol, O | 1 |
| Chen, JJ; Dashtipour, K; Lyons, KE; Swope, DM | 1 |
| Stocchi, F | 1 |
| Boroojerdi, B; Häck, HJ; Kassubek, J; Naumann, M; Odin, P; Reichmann, H; Schwarz, M; Wüllner, U | 1 |
| Häck, HJ; Leffers, KW; Schnitzler, A | 1 |
| Boroojerdi, B; Braun, M; Scheller, DK; Wolff, HM | 1 |
| Boroojerdi, B; Fichtner, A; Giladi, N; Poewe, W | 1 |
| Cho, YS; Kwon, HJ | 1 |
| Hinnell, C; Hulse, N; Martin, A; Samuel, M | 1 |
| Anderson, T; Boroojerdi, B; Chaudhuri, KR; Dioszeghy, P; Fine, J; Hill, D; Honczarenko, K; Kassubek, J; Kies, B; Myllyla, V; Nikl, J; Poewe, W; Rudzinska, M; Steiger, M; Surmann, E; Tolosa, E; Trenkwalder, C; Whitesides, J; Zucconi, M | 1 |
| Munhoz, RP; Teive, HA | 1 |
| Sanford, M; Scott, LJ | 2 |
| Boroojerdi, B; Ghys, L; Surmann, E; Whitesides, J | 1 |
| Chitnis, S; Dewey, RB; Jaffery, M | 1 |
| Ceballos-Baumann, A; Häck, HJ | 1 |
| Bentivoglio, AR; De Nigris, F; Fasano, A; Guidubaldi, A | 1 |
| Perez-Lloret, S; Rascol, O; Ratti, PL; Rey, MV | 1 |
| Boroojerdi, B; Elmer, LW; Jankovic, J; Surmann, E | 1 |
| Poewe, W; Seppi, K; Sprenger, FS | 1 |
| Bernardi, G; Di Giorgio, A; Marfia, GA; Pierantozzi, M; Pisani, V; Rocchi, C; Stanzione, P; Stefani, A | 1 |
| Boroojerdi, B; Ghys, L; Giladi, N; Grieger, F; LeWitt, P; Oertel, W | 1 |
| Avanzino, L; Bonuccelli, U; Caltagirone, C; Ceravolo, R; Dell'Agnello, G; Fabbrini, G; Guadagna, M; Mancini, M; Meco, G; Morgante, F; Pierantozzi, M; Rossi, A; Ruggieri, S; Silvestrini, M; Spezia, R; Stocchi, F; Tessitore, A | 1 |
| Cen, X; Du, G; Fu, F; Guan, X; Li, Y; Liu, W; Tian, J; Wang, H; Ye, L; Yu, P; Yu, X; Zhang, J | 1 |
| Boroojerdi, B; LeWitt, PA; Poewe, W; Surmann, E | 1 |
| Pae, CU | 1 |
| Behrens, S; Sommerville, K | 1 |
| Mucke, HA | 1 |
| Morgan, JC; Sethi, KD | 2 |
| Luessi, F; Poewe, W | 1 |
| Pfeiffer, RF | 1 |
| Easthope, SE; Reynolds, NA; Wellington, K | 1 |
| LeWitt, P | 1 |
| Babic, T | 1 |
| Zareba, G | 1 |
| Wasielewski, S | 1 |
| Boroojerdi, B; Häck, HJ; Korczyn, AD; Reichmann, H | 1 |
| Boroojerdi, B; Jankovic, J; Rajput, A; Rao, J; Waters, C; Watts, RL | 1 |
| Splinter, MY | 1 |
| Chaudhuri, KR; Naidu, Y | 1 |
| Goiny, M; Hu, XJ; Kehr, J; Scheller, DK | 1 |
| LeWitt, PA; Lyons, KE; Pahwa, R | 1 |
| Christie, J | 1 |
| Boroojerdi, B; Jankovic, J; Martin, W; Watts, RL | 1 |
| O'Neill, MJ; Witkin, JM | 1 |
| Korczyn, AD | 1 |
| Boroojerdi, B; Martignoni, E; Oertel, WH; Poewe, WH; Quinn, N; Rascol, O; Rupp, M; Tolosa, E | 1 |
| Jankovic, J; Kenney, C | 1 |
| Boroojerdi, B; Burn, DJ; Clarke, CE; Giladi, N; Korczyn, AD; Schapira, AH | 1 |
| Baldwin, CM; Keating, GM | 2 |
| Steiger, M | 1 |
| Rosenberg, R | 1 |
| Jankovic, J | 1 |
| Chatsis, V | 1 |
| Timmerman, W | 1 |
| Chicheportiche, R; Crouzel, C; Hantraye, P; Kamenka, JM; Ponchant, M; Varastet, M | 1 |
| Asin, KE; Domino, EF; Nikkel, A; Shiosaki, K | 1 |
| Brancazio, P; Calabrese, VP; Cefali, E; Lloyd, KA; Martin, P; Sica, D; Wall, J | 1 |
| Retz, W; Riederer, P; Rösler, M; Thome, J | 1 |
| Barrett, R; Bennett, JP; Calabrese, VP; Calne, DB; Chase, TN; Hutton, JT; Juncos, JL; Koller, WC; LeWitt, PA; Metman, LV; Morris, JL; Pahwa, R; Samii, A; Tsui, JK; Waters, CH | 1 |
| Accornero, N; Agnoli, A; Casacchia, M; Ruggieri, S; Volante, F | 1 |
45 review(s) available for thiophenes and Parkinson Disease
| Article | Year |
|---|---|
A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
Topics: Activities of Daily Living; Dopamine Agonists; Humans; Parkinson Disease; Randomized Controlled Trials as Topic; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2022 |
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamines; Botulinum Toxins, Type A; Deep Brain Stimulation; Dopamine Agonists; Drug Combinations; Duloxetine Hydrochloride; Humans; Levodopa; Naloxone; Oxycodone; Pain; Pain Management; Pain Measurement; Pain Threshold; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2020 |
Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Parkinson Disease; Quality of Life; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2021 |
Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.
Topics: Bromocriptine; Cluster Analysis; Dopamine Agonists; Drug Therapy, Combination; Humans; Indoles; Levodopa; Network Meta-Analysis; Parkinson Disease; Picolinic Acids; Pramipexole; Selegiline; Tetrahydronaphthalenes; Thiophenes | 2017 |
Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
Topics: Dopamine Agonists; Drug Substitution; Humans; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Hiccups in Parkinson's disease: an analysis of cases reported in the European pharmacovigilance database and a review of the literature.
Topics: Aged; Aged, 80 and over; Benzothiazoles; Dopamine Agonists; Female; Hiccup; Humans; Male; Middle Aged; Parkinson Disease; Pharmacovigilance; Pramipexole; Tetrahydronaphthalenes; Thiophenes | 2017 |
Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.
Topics: Humans; Parkinson Disease; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes | 2017 |
Pain in Parkinson's disease: facts and uncertainties.
Topics: Analgesics; Consensus; Humans; Pain; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2018 |
Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: A meta-analysis of randomized placebo-controlled trials.
Topics: Dopamine Agonists; Humans; Mental Disorders; Parkinson Disease; Psychotropic Drugs; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2018 |
Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Indoles; Parkinson Disease; Pramipexole; Quality of Life; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2019 |
The efficacy and safety of rotigotine transdermal patch for the treatment of sleep disorders in Parkinson's disease: a meta-analysis.
Topics: Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2019 |
Wearing off, dyskinesia, and the use of continuous drug delivery in Parkinson's disease.
Topics: Animals; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Dyskinesia, Drug-Induced; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2013 |
The development of the rotigotine transdermal patch: a historical perspective.
Topics: Animals; Dopamine Agonists; Drug Evaluation, Preclinical; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2013 |
Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Dopamine Agonists; Humans; Multicenter Studies as Topic; Parkinson Disease; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2013 |
Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.
Topics: Dopamine Agonists; Humans; Parkinson Disease; Placebos; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
Effects of rotigotine on Parkinson's disease-related sleep disturbances.
Topics: Animals; Clinical Trials as Topic; Dopamine Agonists; Drug Evaluation, Preclinical; Humans; Parkinson Disease; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2013 |
Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
Topics: Administration, Cutaneous; Dopamine; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2013 |
Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Humans; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2014 |
Rotigotine: the first new chemical entity for transdermal drug delivery.
Topics: Administration, Cutaneous; Chemical Phenomena; Clinical Trials as Topic; Dopamine Agonists; Drug Delivery Systems; Humans; Molecular Structure; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2014 |
An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Comorbidity; Dopamine Agonists; Drug Interactions; Evidence-Based Medicine; Humans; Parkinson Disease; Practice Guidelines as Topic; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2015 |
Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances.
Topics: Administration, Cutaneous; Antiparkinson Agents; Carbidopa; Delayed-Action Preparations; Dopamine Agonists; Drug Combinations; Gels; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2016 |
Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis.
Topics: Aged; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2016 |
Rotigotine transdermal system for the treatment of Parkinson's disease.
Topics: Administration, Cutaneous; Drug Interactions; Humans; Parkinson Disease; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 2008 |
Rotigotine transdermal delivery for the treatment of Parkinson's disease.
Topics: Administration, Cutaneous; Antiparkinson Agents; Controlled Clinical Trials as Topic; Disorders of Excessive Somnolence; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Nausea; Parkinson Disease; PubMed; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2009 |
Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Humans; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2009 |
Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Topics: Administration, Cutaneous; Dopamine Agonists; Dosage Forms; Evidence-Based Medicine; Humans; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2010 |
Control of autophagy with small molecules.
Topics: Alzheimer Disease; Autophagy; Cell Death; Humans; Neurodegenerative Diseases; Parkinson Disease; Proteins; Pyrimidinones; Signal Transduction; Small Molecule Libraries; Structure-Activity Relationship; Thiophenes | 2010 |
Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Delayed-Action Preparations; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2011 |
Spotlight on rotigotine transdermal patch in Parkinson's disease.
Topics: Animals; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2011 |
Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2013 |
Drug safety evaluation of rotigotine.
Topics: Administration, Cutaneous; Antiparkinson Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine Agonists; Evidence-Based Medicine; Humans; Parkinson Disease; Patient Safety; Risk Assessment; Risk Factors; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2012 |
Rotigotine Schwarz Pharma.
Topics: Animals; Clinical Trials as Topic; Dopamine Agonists; Drugs, Investigational; Humans; Parkinson Disease; Receptors, Dopamine D2; Restless Legs Syndrome; Technology, Pharmaceutical; Tetrahydronaphthalenes; Thiophenes | 2003 |
Clinical studies with transdermal rotigotine in early Parkinson's disease.
Topics: Administration, Cutaneous; Antiparkinson Agents; Clinical Trials as Topic; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2005 |
A promising new technology for Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Antiparkinson Agents; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2005 |
Rotigotine: in Parkinson's disease.
Topics: Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2005 |
Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Dopamine Agonists; Humans; Parkinson Disease; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2006 |
Rotigotine for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Humans; Parkinson Disease; Practice Patterns, Physicians'; Tetrahydronaphthalenes; Thiophenes | 2006 |
Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dopamine Agonists; Humans; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2007 |
Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Clinical Trials as Topic; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2007 |
AMPA receptor potentiators: application for depression and Parkinson's disease.
Topics: Animals; Depressive Disorder; Drug Synergism; Excitatory Amino Acid Agonists; Humans; Parkinson Disease; Receptors, AMPA; Sulfonamides; Thiophenes | 2007 |
Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2007 |
Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
Topics: Administration, Cutaneous; Databases as Topic; Dopamine Agonists; Humans; Parkinson Disease; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes | 2007 |
Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.
Topics: Administration, Cutaneous; Animals; Brain; Catechol O-Methyltransferase Inhibitors; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Humans; Parkinson Disease; Receptors, Dopamine; Tetrahydronaphthalenes; Thiophenes | 2008 |
Parkinson's disease and movement disorders: moving forward.
Topics: Dopamine Agonists; Humans; Methyldopa; Movement Disorders; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2008 |
Free radicals in Alzheimer's dementia: currently available therapeutic strategies.
Topics: Alzheimer Disease; Antioxidants; Drugs, Chinese Herbal; Free Radical Scavengers; Free Radicals; Humans; Monoamine Oxidase Inhibitors; Neurons; Parkinson Disease; Piperazines; Psychotropic Drugs; Selegiline; Thiophenes; Vitamins | 1998 |
52 trial(s) available for thiophenes and Parkinson Disease
| Article | Year |
|---|---|
Rotigotine for nocturnal hypokinesia in Parkinson's disease: Quantitative analysis of efficacy from a randomized, placebo-controlled trial using an axial inertial sensor.
Topics: Accelerometry; Aged; Dopamine Agonists; Female; Humans; Hypokinesia; Male; Middle Aged; Parkinson Disease; Sleep; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Topics: Aged; Antiparkinson Agents; Asian People; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
Efficacy and safety of rotigotine in elderly patients with Parkinson's disease in comparison with the non-elderly: a post hoc analysis of randomized, double-blind, placebo-controlled trials.
Topics: Age Factors; Aged; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes | 2018 |
Effectiveness of Rotigotine plus intensive and goal-based rehabilitation versus Rotigotine alone in "de-novo" Parkinsonian subjects: a randomized controlled trial with 18-month follow-up.
Topics: Aged; Analysis of Variance; Dopamine Agonists; Exercise Therapy; Female; Follow-Up Studies; Goals; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Single-Blind Method; Tetrahydronaphthalenes; Thiophenes; Time Factors; Treatment Outcome | 2018 |
Randomized, double-blind, crossover study of the adhesiveness of two formulations of rotigotine transdermal patch in patients with Parkinson's disease.
Topics: Adhesiveness; Administration, Cutaneous; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2018 |
Rotigotine Improves Abnormal Circadian Rhythm of Blood Pressure in Parkinson's Disease.
Topics: Aged; Autonomic Nervous System; Blood Pressure; Circadian Rhythm; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2018 |
A noninterventional study evaluating the effectiveness of rotigotine and levodopa combination therapy in younger versus older patients with Parkinson's disease.
Topics: Aged; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Sleep; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2018 |
Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease.
Topics: Aged; Disorders of Excessive Somnolence; Dopamine Agonists; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2019 |
Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
Topics: Actigraphy; Aged; Clinical Decision-Making; Dopamine Agonists; Female; Humans; Male; Parkinson Disease; Pilot Projects; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Wearable Electronic Devices | 2019 |
The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Topics: Adolescent; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Electrocardiography; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Survival Analysis; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2013 |
Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apathy; Dopamine Agonists; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Mood Disorders; Parkinson Disease; Psychiatric Status Rating Scales; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2013 |
Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Cutaneous; Age Factors; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2013 |
Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations.
Topics: Adult; Biological Availability; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Humans; Male; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2013 |
Associations between severity of motor function and nonmotor symptoms in Parkinson's disease: a post hoc analysis of the RECOVER Study.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2014 |
Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Dopamine Agonists; Female; Humans; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease; Prospective Studies; Tetrahydronaphthalenes; Thiophenes | 2014 |
A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2014 |
Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Cutaneous; Adult; Aged; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2014 |
Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesias; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Sex Factors; Tetrahydronaphthalenes; Thiophenes | 2014 |
Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Double-Blind Method; Female; Humans; Indoles; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2014 |
Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Male; Middle Aged; Pain Measurement; Parkinson Disease; Patient Satisfaction; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2015 |
Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Caregivers; Cross-Sectional Studies; Dopamine Agonists; Female; Germany; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Physicians; Pilot Projects; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Young Adult | 2015 |
Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Drug Substitution; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Tetrahydronaphthalenes; Thiophenes | 2015 |
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Benzothiazoles; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2015 |
Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Topics: Activities of Daily Living; Administration, Cutaneous; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies; Tetrahydronaphthalenes; Thiophenes; Time Factors; Treatment Outcome | 2015 |
Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Apathy; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Quality of Life; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2015 |
A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
Topics: Aged; Chronic Pain; Dopamine Agonists; Double-Blind Method; Female; Humans; Internationality; Male; Middle Aged; Pain Measurement; Parkinson Disease; Pilot Projects; Prospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2016 |
Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Topics: Adult; Aged; China; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2016 |
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Apathy; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2016 |
Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Depression; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome; Vomiting | 2016 |
Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study.
Topics: Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Polysomnography; Severity of Illness Index; Sleep Stages; Sleep Wake Disorders; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes | 2016 |
Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Topics: Aged; Disease Progression; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes | 2016 |
Patients' perception of Parkinson's disease-associated pain following initiation of rotigotine: a multicenter non-interventional study.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Aged, 80 and over; Austria; Dopamine Agonists; Female; Follow-Up Studies; Germany; Humans; Male; Middle Aged; Pain; Parkinson Disease; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes | 2017 |
Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Dopamine Agonists; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Parkinson Disease; Quinolines; Tetrahydronaphthalenes; Thiophenes | 2008 |
Transdermal rotigotine for the perioperative management of Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anesthesia, General; Anesthesiology; Attitude of Health Personnel; Dopamine Agonists; Feasibility Studies; Female; Humans; Male; Middle Aged; Neurology; Parkinson Disease; Perioperative Care; Physicians; Prospective Studies; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2010 |
High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Humans; Male; Parkinson Disease; Patient Compliance; Patient Satisfaction; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2010 |
Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease.
Topics: Aged; Dopamine Agonists; Female; Humans; Male; Middle Aged; Movement Disorders; Parkinson Disease; Prospective Studies; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes | 2010 |
Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).
Topics: Adult; Aged; Aged, 80 and over; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Motor Activity; Parkinson Disease; Severity of Illness Index; Sleep Wake Disorders; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2011 |
Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline.
Topics: Dopamine Agonists; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Quality of Life; Severity of Illness Index; Sleep; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2011 |
Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Disorders of Excessive Somnolence; Dopamine Agonists; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Prospective Studies; Tetrahydronaphthalenes; Thiophenes | 2012 |
Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Sleep; Tetrahydronaphthalenes; Thiophenes; Time Factors | 2011 |
Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Dopamine Agonists; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2012 |
Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Dopamine Agonists; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2013 |
A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Parkinson Disease; Psychiatric Status Rating Scales; Quality of Life; Thiophenes; Treatment Outcome | 2012 |
Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.
Topics: Activities of Daily Living; Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Dopamine Agonists; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Time Factors | 2013 |
A controlled trial of rotigotine monotherapy in early Parkinson's disease.
Topics: Activities of Daily Living; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Movement; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Time Factors | 2003 |
Rotigotine monotherapy in early Parkinson's disease.
Topics: Activities of Daily Living; Adult; Double-Blind Method; Fatigue; Female; Humans; Male; Nausea; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2004 |
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease.
Topics: Administration, Cutaneous; Aged; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Time Factors | 2007 |
Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
Topics: Administration, Cutaneous; Aged; Dopamine Agonists; Double-Blind Method; Drug Administration Routes; Drug Administration Schedule; Dyskinesia, Drug-Induced; Erythema; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Pruritus; Tetrahydronaphthalenes; Thiophenes; Time Factors; Treatment Outcome | 2007 |
Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Case-Control Studies; Dopamine Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes | 2007 |
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Benzothiazoles; Dopamine Agonists; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson Disease; Placebos; Pramipexole; Severity of Illness Index; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2007 |
Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole.
Topics: Administration, Cutaneous; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Patient Selection; Tetrahydronaphthalenes; Thiophenes | 2007 |
Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.
Topics: Administration, Cutaneous; Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine D2; Tetrahydronaphthalenes; Therapeutic Equivalency; Thiophenes; Treatment Outcome | 2001 |
75 other study(ies) available for thiophenes and Parkinson Disease
| Article | Year |
|---|---|
Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Female; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes; Urinary Bladder | 2022 |
Pharmacological Rescue with SR8278, a Circadian Nuclear Receptor REV-ERBα Antagonist as a Therapy for Mood Disorders in Parkinson's Disease.
Topics: Animals; Humans; Isoquinolines; Mice; Mood Disorders; Neurodegenerative Diseases; Nuclear Receptor Subfamily 1, Group D, Member 1; Oxidopamine; Parkinson Disease; Quality of Life; Thiophenes; Tyrosine 3-Monooxygenase | 2022 |
Tolerability of overnight rotigotine transdermal patch combined with intrajejunal levodopa infusion at 1 year: a 24-h treatment option in Parkinson's disease.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Quality of Life; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2022 |
(Re)Formulating rotigotine: a potential molecule with unmet needs.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2022 |
Luminescent conjugated oligothiophenes distinguish between α-synuclein assemblies of Parkinson's disease and multiple system atrophy.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Diagnosis, Differential; Female; Fluorescent Dyes; Humans; Luminescent Measurements; Male; Middle Aged; Multiple System Atrophy; Optical Imaging; Parkinson Disease; Thiophenes | 2019 |
Impulse control disorder-linked hypersexuality complicated by disseminated gonococcal infection in a patient with Parkinson's disease.
Topics: Amantadine; Apomorphine; Compulsive Behavior; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gonorrhea; Humans; Levodopa; Middle Aged; Parkinson Disease; Sexual Dysfunctions, Psychological; Tetrahydronaphthalenes; Thiophenes | 2020 |
Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
Topics: Administration, Cutaneous; Cohort Studies; Dopamine Agonists; Humans; Parkinson Disease; Plasma; Polymers; Tetrahydronaphthalenes; Thiophenes | 2020 |
Real-world safety and effectiveness of rotigotine in patients with Parkinson's disease: analysis of a post-marketing surveillance study in Japan.
Topics: Aged; Aged, 80 and over; Dopamine Agonists; Humans; Japan; Parkinson Disease; Product Surveillance, Postmarketing; Prospective Studies; Tetrahydronaphthalenes; Thiophenes | 2022 |
How to introduce a rotigotine patch to Parkinson's disease patients taking oral dopamine agonists.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes | 2020 |
Rotigotine patch prescription in inpatients with Parkinson's disease: evaluating prescription accuracy, delirium and end-of-life use.
Topics: Death; Delirium; Humans; Inpatients; Parkinson Disease; Prescriptions; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes | 2021 |
Idiopathic Parkinson's Disease at the End of Life: A Retrospective Evaluation of Symptom Prevalence, Pharmacological Symptom Management and Transdermal Rotigotine Dosing.
Topics: Administration, Cutaneous; Death; Dopamine Agonists; Humans; Parkinson Disease; Prevalence; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2021 |
Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cross-Sectional Studies; Dopamine Agonists; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Regression Analysis; Retrospective Studies; Sleep; Tetrahydronaphthalenes; Thiophenes | 2021 |
Rotigotine may control drooling in patients with Parkinson's Disease: Preliminary findings.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Sialorrhea; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2017 |
Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report.
Topics: Aged; Carbidopa; Drug Combinations; Gels; Humans; Levodopa; Male; Parkinson Disease; Receptors, Dopamine; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2017 |
The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Cognition Disorders; Dopamine Agonists; Female; Humans; Male; Parkinson Disease; Product Surveillance, Postmarketing; Retrospective Studies; Sleep Wake Disorders; Spain; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome; Urination Disorders | 2018 |
Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects.
Topics: Administration, Intranasal; Animals; Brain; Disease Models, Animal; Dopamine Agonists; Drug Carriers; Drug Delivery Systems; Lactoferrin; Male; Nanoparticles; Neuroprotective Agents; Nose; Parkinson Disease; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tetrahydronaphthalenes; Thiophenes; Tissue Distribution | 2018 |
An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2018 |
Transdermal rotigotine patch in Parkinson's disease with a history of intestinal operation.
Topics: Adult; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Intestine, Small; Malabsorption Syndromes; Male; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2018 |
The combination of levomepromazine (methotrimeprazine) and rotigotine enables the safe and effective management of refractory nausea and vomiting in a patient with idiopathic Parkinson's disease.
Topics: Administration, Cutaneous; Aged; Antiparkinson Agents; Antipsychotic Agents; Dopamine Agonists; Female; Humans; Methotrimeprazine; Nausea; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome; Vomiting | 2019 |
Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Delayed-Action Preparations; Dopamine Agonists; Female; Humans; Indoles; Male; Middle Aged; Parkinson Disease; Pramipexole; Sex Factors; Tetrahydronaphthalenes; Thiophenes | 2019 |
Risk of Parkinson disease in Sjögren syndrome administered ineffective immunosuppressant therapies: A nationwide population-based study.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Comorbidity; Female; Humans; Hydroxychloroquine; Immunosuppression Therapy; Incidence; Male; Methylprednisolone; Middle Aged; Muscarinic Agonists; National Health Programs; Parkinson Disease; Pilocarpine; Quinuclidines; Retrospective Studies; Risk Factors; Sjogren's Syndrome; Taiwan; Thiophenes | 2019 |
Effects of rotigotine and rotigotine extended-release microsphere therapy on myocardial ischemic injury in mice.
Topics: Animals; Cardiotonic Agents; Chlorpromazine; Creatine Kinase, MB Form; Dopamine Agonists; Isoproterenol; Male; Mice; Microspheres; Models, Animal; Myocardial Ischemia; Myocytes, Cardiac; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Troponin I | 2019 |
Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson's disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition; Dopamine Agonists; Female; Humans; Levodopa; Male; Parkinson Disease; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2019 |
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Injections, Intramuscular; Male; Microspheres; Neutrophils; No-Observed-Adverse-Effect Level; Organ Size; Ovary; Parkinson Disease; Prolactin; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Thiophenes; Toxicity Tests, Subchronic | 2013 |
Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Motor Skills Disorders; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2013 |
Rotigotine for anxiety during wearing-off in Parkinson's disease with dementia.
Topics: Aged; Anxiety; Dementia; Dopamine Agonists; Female; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2013 |
Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation.
Topics: Benzothiazoles; DNA Mutational Analysis; DNA Polymerase gamma; DNA-Directed DNA Polymerase; Dopamine Agonists; Duloxetine Hydrochloride; Dysarthria; Female; Hereditary Sensory and Motor Neuropathy; Humans; Middle Aged; Mitochondria; Ophthalmoplegia; Parkinson Disease; Pramipexole; Thiophenes; Tomography, Emission-Computed, Single-Photon | 2013 |
Synthesis and SAR study of a novel series of dopamine receptor agonists.
Topics: Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2014 |
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study.
Topics: Administration, Cutaneous; Administration, Oral; Age Factors; Aged; Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Sex Factors; Tetrahydronaphthalenes; Thiophenes | 2014 |
The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
Topics: Animals; Binding Sites; Cell Line; Cell Proliferation; Disease Models, Animal; Dopaminergic Neurons; Drug Evaluation, Preclinical; Forkhead Box Protein O3; Forkhead Transcription Factors; Histone Deacetylase Inhibitors; Humans; MCF-7 Cells; Molecular Docking Simulation; Neuroprotective Agents; Parkinson Disease; Protein Binding; Protein Structure, Tertiary; Pyrimidinones; Rats; Sirtuin 2; Structure-Activity Relationship; Thiophenes | 2015 |
Inhibition of i-NOS but not n-NOS protects rat primary cell cultures against MPP(+)-induced neuronal toxicity.
Topics: Amidines; Animals; Antibodies, Monoclonal; Astrocytes; Benzylamines; Cell Count; Cells, Cultured; Dopaminergic Neurons; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glial Fibrillary Acidic Protein; Mesencephalon; Microglia; Neuroprotective Agents; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Parkinson Disease; Picolines; Primary Cell Culture; Rats, Wistar; Thiophenes; Tyrosine; Tyrosine 3-Monooxygenase | 2015 |
A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson's disease resolved with rotigotine: a case report.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dopamine Agonists; Female; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2014 |
Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson's Disease.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Deglutition; Deglutition Disorders; Dopamine Agonists; Female; Humans; Male; Parkinson Disease; Retrospective Studies; Tetrahydronaphthalenes; Thiophenes | 2015 |
A potential tailor-made hyaluronic acid buccal delivery system comprising rotigotine for Parkinson's disease?
Topics: Administration, Buccal; Cell Line; Cysteine; Delayed-Action Preparations; Dopamine Agonists; Humans; Hyaluronic Acid; Parkinson Disease; Sulfhydryl Compounds; Tetrahydronaphthalenes; Thiophenes | 2015 |
Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study.
Topics: Aged; Aged, 80 and over; Biomechanical Phenomena; Dopamine Agonists; Female; Gait Disorders, Neurologic; Humans; Locomotion; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2015 |
[Dopamine receptor agonists: new forms and new possibilities in the treatment of Parkinson's disease].
Topics: Administration, Cutaneous; Dopamine Agonists; Female; Humans; Male; Motor Activity; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2015 |
Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Parkinson Disease; Polysomnography; Severity of Illness Index; Sleep; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2015 |
The Chemical Molecule B355252 is Neuroprotective in an In Vitro Model of Parkinson's Disease.
Topics: Animals; Apoptosis; Caspase 3; Cell Death; Mice; Mitochondria; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Reactive Oxygen Species; Signal Transduction; Thiophenes | 2016 |
[Diurnal observation of antecollis in Parkinson's disease to determine the dopamine agonist dose: A case report].
Topics: Circadian Rhythm; Dopamine Agonists; Dose-Response Relationship, Drug; Gait Disorders, Neurologic; Humans; Male; Middle Aged; Parkinson Disease; Posture; Tetrahydronaphthalenes; Thiophenes | 2016 |
Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Selegiline; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2016 |
[Continued Use of Rotigotine Transdermal Patches for Parkinson Disease].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Risk Factors; Tetrahydronaphthalenes; Thiophenes | 2016 |
Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
Topics: Administration, Cutaneous; Aged; Dermatitis, Allergic Contact; Dopamine Agonists; Humans; Parkinson Disease; Patch Tests; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2016 |
Effects of Rotigotine on REM Sleep Behavior Disorder in Parkinson Disease.
Topics: Aged; Dopamine Agonists; Female; Hong Kong; Humans; Male; Parkinson Disease; Polysomnography; Prospective Studies; REM Sleep Behavior Disorder; Severity of Illness Index; Sleep, REM; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch; Treatment Outcome | 2016 |
An observational clinical and video-polysomnographic study of the effects of rotigotine in sleep disorder in Parkinson's disease.
Topics: Aged; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Parkinson Disease; Polysomnography; Quality of Life; Sleep Stages; Sleep Wake Disorders; Surveys and Questionnaires; Tetrahydronaphthalenes; Thiophenes; Video Recording | 2017 |
Higher levels of apomorphine and rotigotine prescribing reduce overall secondary healthcare costs in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Apomorphine; Drug Prescriptions; England; Health Care Costs; Humans; Middle Aged; Parkinson Disease; Practice Patterns, Physicians'; Tetrahydronaphthalenes; Thiophenes | 2016 |
Novel UHPLC-MS/MS method for the determination of rotigotine in the plasma of patients with Parkinson's disease.
Topics: Chromatography, High Pressure Liquid; Dopamine Agonists; Humans; Limit of Detection; Linear Models; Parkinson Disease; Reproducibility of Results; Tandem Mass Spectrometry; Tetrahydronaphthalenes; Thiophenes | 2017 |
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress.
Topics: Aged; Analysis of Variance; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Dipeptides; Dopamine Agents; Electrochemical Techniques; Female; Homocysteine; Humans; Levodopa; Male; Middle Aged; Oxidative Stress; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Time Factors; Tyrosine | 2017 |
Rotigotine: Parkinson's disease: a step backward.
Topics: Administration, Cutaneous; Clinical Trials as Topic; Dopamine Agonists; France; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2008 |
The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment.
Topics: Dopamine; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2010 |
[Pharmacology sheet. Transdermal Rotigotine (Neupro)].
Topics: Administration, Cutaneous; Antiparkinson Agents; Dopamine Agonists; Humans; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2010 |
Hypersexuality and compulsive over-eating associated with transdermal dopamine agonist therapy.
Topics: Antiparkinson Agents; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Hyperphagia; Hypokinesia; Male; Parkinson Disease; Sexual Dysfunction, Physiological; Tetrahydronaphthalenes; Thiophenes | 2011 |
Rotigotine-induced nail dyschromia in a patient with Parkinson disease.
Topics: Aged, 80 and over; Dopamine Agonists; Humans; Male; Nail Diseases; Nails; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2011 |
Safety and efficacy of rotigotine in individuals with Parkinson's disease aged 75 and older.
Topics: Aged; Aged, 80 and over; Dopamine Agonists; Female; Humans; Male; Medication Adherence; Parkinson Disease; Prospective Studies; Tetrahydronaphthalenes; Thiophenes | 2011 |
In brief: transdermal rotigotine (Neupro).
Topics: Antiparkinson Agents; Parkinson Disease; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Transdermal Patch | 2012 |
The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Autonomic Nervous System; Blood Pressure; Cardiovascular Physiological Phenomena; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Hand Strength; Heart Rate; Humans; Male; Middle Aged; Parkinson Disease; Respiration; Statistics, Nonparametric; Tetrahydronaphthalenes; Thiophenes; Valsalva Maneuver; Young Adult | 2012 |
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
Topics: Animals; Atrophy; Blood Pressure; Body Temperature; Body Weight; Bone Marrow; Dopamine Agonists; Eating; Electrocardiography; Female; Injections, Intramuscular; Macaca fascicularis; Male; Microspheres; Mortality; Organ Size; Parkinson Disease; Polyglactin 910; Prolactin; Pulmonary Embolism; Tetrahydronaphthalenes; Thiophenes; Thymus Gland; Toxicity Tests, Subchronic | 2013 |
Use of antidepressants for depression in patients with Parkinson's disease.
Topics: Antidepressive Agents; Depression; Duloxetine Hydrochloride; Humans; Parkinson Disease; Positron-Emission Tomography; Thiophenes | 2013 |
Non-oral drug delivery in Parkinson's disease: a summary from the symposium at the 7th International Congress of Parkinson's Disease and Movement Disorders. 10-14 November 2002, Miami, FL, USA.
Topics: Antiparkinson Agents; Congresses as Topic; Humans; Intestinal Absorption; Levodopa; Movement Disorders; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2003 |
Rotigotine: a viewpoint by Peter LeWitt.
Topics: Dopamine Agonists; Humans; Parkinson Disease; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes | 2005 |
Rotigotine: a viewpoint by Tomislav Babic.
Topics: Antiparkinson Agents; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2005 |
[A new Parkinson patch from Schwarz Pharma is on the market].
Topics: Administration, Cutaneous; Antiparkinson Agents; Clinical Trials as Topic; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2006 |
[Transdermal rotigotine as monotherapy for Parkinson disease].
Topics: Administration, Cutaneous; Antiparkinson Agents; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2006 |
Rotigotine transdermal system for perioperative administration.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Anesthesia, General; Dopamine Agonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Perioperative Care; Randomized Controlled Trials as Topic; Surgical Procedures, Operative; Tetrahydronaphthalenes; Thiophenes | 2007 |
Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agonists; Down-Regulation; Drug Administration Schedule; Extracellular Fluid; Infusion Pumps, Implantable; Male; Microdialysis; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Synaptic Transmission; Tetrahydronaphthalenes; Thiophenes; Time Factors | 2007 |
The use of transdermal rotigotine in a patient with advanced Parkinson's disease and dysphagia.
Topics: Administration, Cutaneous; Aged, 80 and over; Deglutition Disorders; Dopamine Agonists; Esophageal Neoplasms; Esophagogastric Junction; Humans; Male; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2007 |
Transdermal therapy in Parkinson's disease.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2007 |
Transdermal rotigotine (Neupro) for Parkinson's disease.
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Parkinson Disease; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2007 |
Notice of redundant publication: "Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease" (Arch Neurol. 2007;64[5]:676-682).
Topics: Administration, Cutaneous; Dopamine Agonists; Humans; Neurology; Parkinson Disease; Publishing; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes | 2007 |
Spotlight on rotigotine in Parkinson's disease.
Topics: Administration, Cutaneous; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes | 2008 |
Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
Topics: Administration, Cutaneous; Adult; Aged; Antiparkinson Agents; Canada; Dopamine Agonists; Drug Approval; Humans; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Dopaminergic receptor agents and the basal ganglia: pharmacological properties and interactions with the GABA-ergic system.
Topics: Animals; Basal Ganglia; Behavior, Animal; Dopamine Agents; gamma-Aminobutyric Acid; Humans; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 1993 |
Synthesis of 3-[18F]fluoromethyl-BTCP and evaluation as a potential PET radioligand for the dopamine transporter in baboons.
Topics: Animals; Brain; Carrier Proteins; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Evaluation Studies as Topic; Fluorine Radioisotopes; Isotope Labeling; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinson Disease; Piperidines; Radioligand Assay; Thiophenes; Tomography, Emission-Computed | 1993 |
The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Macaca nemestrina; Male; Parkinson Disease; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Rotation; Tetrahydronaphthalenes; Thiophenes | 1997 |
N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism.
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps; Male; Metabolic Clearance Rate; Middle Aged; Neurologic Examination; Parkinson Disease; Receptors, Dopamine D2; Tetrahydronaphthalenes; Thiophenes | 1998 |
Parkinson's tremor, relief by an antiaminic drug (BC 105). Discussion on the biochemical pathogenesis of Parkinsonian tremor.
Topics: Adult; Aged; Benzocycloheptenes; Dihydroxyphenylalanine; Ergolines; Female; Histamine H1 Antagonists; Humans; Male; Middle Aged; Parkinson Disease; Piperidines; Promethazine; Thiophenes; Tremor; Trihexyphenidyl | 1972 |